Why Oragenics (OGEN) Stock Is Getting Hammered

Oragenics Inc OGEN shares are trading lower by 45.5% to $0.58 during Wednesday’s session after the company announced a $4.45 million public offering of 8,106,584 shares at $0.55 per share.

The public offering is expected to close around September 5, pending standard closing conditions, and is anticipated to raise approximately $4.45 million before fees and expenses.

The funds will be used for the development of the company’s ONP-002 product and for general corporate purposes. Dawson James Securities, Inc. is the sole placement agent for the offering.

Read Also: July Job Openings Fall To 3-Year Lows, Gap With Unemployment Narrows To Near Parity: Traders Raise Rate Cut Bets

Should I Sell My OGEN Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of Oragenics have lost 82.44% year to date. This compares to the average annual return of -70.43%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

OGEN has a 52-week high of $7.74 and a 52-week low of $0.54.